A label we don't need To the Editor: The United Nations (UN; New York) agency that sets food standards-the Codex Alimentarius (Latin for 'Food Code,' commonly called 'Codex' for short)-recently reached an impasse on the labeling of food containing products derived from recombinant DNA technology. It decided neither to recommend nor to establish compulsory labeling for foods with ingredients from recombinant DNAmodified organisms-but you' d never know that from the spin.
The Codex was established in 1963 by two UN entities, the Food & Agricultural Organization (FAO; Rome) and the World Health Organization (WHO; Geneva). Operating through various committees, one of which is the Committee on Food Labeling (CCFL), Codex develops voluntary, consensus, international standards to promote consumer health and fair trade in food products in international commerce. Codex is important for another, unobvious reason. In accordance with specific language in the World Trade Organization's (WTO, Geneva) trade agreements, any country that incorporates the Codex standards into its domestic laws is automatically assumed to be acting in compliance with WTO strictures 1 . Thus, Codex provides a legal safe-haven for nations whose policies or actions may be challenged by WTO complaints.
For almost two decades, the CCFL has dealt with the (unnecessarily) contentious issue of whether foods derived from crops modified with recombinant DNA technology should have to be labeled as such. The obvious question is whether these products are sufficiently unique or pose dangers that should require such labeling. The scientific community has known the answer for a very long time. As Nature editorialized in 1992, "the same physical and biological laws govern the response of organisms modified by modern molecular and cellular methods and those produced by classical methods….
[Therefore] no conceptual distinction exists between genetic modification of plants and microorganisms by classical methods or by molecular techniques that modify DNA and transfer genes" 2 . The US Food and Drug Administration (FDA) has explicitly rejected the labeling of food to indicate that it contains ingredients produced with recombinant DNA technology, as is the case for other genetic modification techniques 3 .
During the deliberations at Codex, Europe has consistently argued for mandatory process-based labeling that reflects the use of certain techniques used in plant breeding, whereas Canada, the United States and other countries have consistently argued against such special labeling, instead endorsing labeling based on food content, safety and nutritional value. Since the early 1990s the issue has been unresolved, with the same arguments presented ad nauseam. The result was an impasse.
In May 2011, in Quebec City, the CCFL reached a truce that had two components. First, nations agreed on the lack of consensus about compulsory labeling for foods derived from modern biotech, and the committee therefore agreed to discontinue further work on definitions and precise rules on this topic. Second, the nations agreed to the adoption of a document entitled "Compilation of Codex Texts Relevant to Labeling of Foods Derived from Modern Biotechnology."
The CCFL sent this compilation to the Codex Alimentarius Commission itself, which met in Geneva in June. The commission accepted the CCFL's compilation document and its decision to discontinue further work. As this action was taken on a consent docket, Codex member nations took no vote; Codex simply accepted the CCFL's May 2011 impasse 4,5 .
Codex's action has been widely misreported, being variously interpreted as either condoning or condemning compulsory labeling of foods derived through the techniques of modern biotech [6] [7] [8] . It does neither; it is simply a compilation that was presented without any value judgments. As described therein, the purpose of the document was "only to recall and assemble in a single document some important elements of guidance from Codex texts, which are relevant to labeling of foods derived from modern biotechnology."
The document further clarifies that "[d]ifferent approaches regarding labeling of foods derived from modern biotechnology are used. Any approach implemented by Codex members should be consistent with already adopted Codex provisions. This document is not intended to suggest or imply that foods derived from modern biotechnology are necessarily different from other foods simply due to their method of production." Far from presenting any new recommendations or requirements, the document notes that it contains only "citations to specific, already existing Codex texts relevant to labeling of foods" 9 . None of these texts specifically addresses labeling of biotech-derived foods.
The document prompted prominent anti-biotech groups, such as Consumers International (London) and Greenpeace (Amsterdam), to immediately proclaim 'victory' in the labeling debate, claiming that Codex had adopted an international standard that protected nations from WTO challenges to mandatory labeling requirements. Consumers International also asserted that the compilation document reflects Codex support for countries in Africa and Latin America to adopt the European mandatory labeling approach 7 .
The Codex compilation does no such thing: the document takes pains to make clear that it does not create an international standard for the labeling of biotechderived foods. The document declares that "different approaches regarding labeling of foods derived from modern biotechnology are used" around the world but emphasizes that Codex does not intend "to suggest or imply that foods derived from modern biotechnology are necessarily different from other foods." The document then cites ten existing Codex standards that countries should comply with in food labeling. To the Editor: Continuing evolution of DNA sequencing has transformed modern biology. Lower sequencing costs coupled with novel sequencing-based assays have led to rapid adoption of next-generation sequencing across diverse areas of life sciences research [1] [2] [3] [4] . Sequencing has moved out of the genome centers into core facilities and individual laboratories where any investigator can access it for modest and progressively declining cost. Although easy to generate in tremendous quantities, sequence data are still difficult to manage and analyze. Sophisticated informatics techniques and supporting infrastructure are needed to make sense of even conceptually simple sequencing experiments, let alone the more complex analysis techniques being developed. The most pressing challenge facing the sequencing community today is providing the informatics infrastructure and accessible analysis methods needed to make it possible for all investigators to realize the power of high-throughput sequencing to advance their research.
A possible solution to this infrastructure challenge comes in the form of cloud computing, a model where computation and storage exist as virtual resources, accessed by means of the internet, which can be dynamically allocated and released as needed 5 . Where previously acquisition of large amounts of computing power required large initial and ongoing costs, the cloud model radically alters this by allowing computing resources and services to be acquired and paid for on demand. Importantly, cloud resources can provide storage and computation at far lower cost than dedicated resources for certain use cases. For several specific applications, effective use of cloud resources has already been demonstrated [6] [7] [8] . In general, however, cloud resources are not provided in a form that can be immediately used by a researcher without informatics expertise. Several commercial vendors provide cloud-based sequence analysis services through the web that hide all complexity of the underlying infrastructure. Yet these contain limited sets of analysis tools, and because they are proprietary solutions, users must give up some control over their own data and risk becoming dependent on a single commercial service for continued data access and analysis. All 'battle-tested' next-generation sequencing analysis practices (e.g., analysis of human variation exemplified by the 1000 Genome Consortium publication 9 ) are open source.
One popular open-source platform that has made substantial progress toward making complex analysis available to researchers is Galaxy 10, 11 . Galaxy enables users to perform analysis using nothing more than a web browser. The environment automatically and transparently tracks every detail of the analysis, allows the construction of complex workflows and permits the results to be documented, shared and published with complete provenance, guaranteeing transparency and reproducibility. Importantly, Galaxy is an extensible platform; nearly any software tool can easily be integrated into Galaxy, and there is an active community of developers ensuring the latest tools are wrapped and made available through the Galaxy Tool Shed (http://usegalaxy.org/ community). Galaxy is provided as a free public service with which thousands of users perform hundreds of thousands of analyses each month. However, this free public resource cannot meet increasing demand without implementing limits on data transfer and computer usage, resulting Therefore, nations with mandatory labeling laws that lack a scientific basiswhich are prohibited by WTO rules-are still vulnerable to WTO challenges. Even the European Union joylessly informed its member states that mandatory labeling "has been on the [CCFL] agenda since 1996 and despite intense negotiations, the US and their allies have managed to prevent any real progress. The US's main motivation is to prevent the adoption of any Codex text which would encourage GM labelling and also make our GM labelling framework WTO compatible…" 10 .
It is important that politicians and regulators do not rely on the widely publicized and biased interpretations of activists with respect to the Codex recommendations (and other international agreements and laws) in formulating national policies. Instead, the various countries that are deliberating about labeling policies for biotech-derived foods should take into consideration several critical facts. First, Codex neither requires nor recommends mandatory labeling; second, nations that adopt mandatory labeling that lacks a scientific basis are vulnerable to WTO challenges and risk economic sanctions; third, the UN's biotech-specific Cartagena Protocol on Biosafety does not address consumer labeling; and fourth, mandatory labeling limits consumers' choices, discourages innovation and impedes advances in food variety, safety and nutrition 11 .
